S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:VKTX

Viking Therapeutics (VKTX) Stock Forecast, Price & News

$21.31
+0.41 (+1.96%)
(As of 05/26/2023 ET)
Compare
Today's Range
$20.61
$21.70
50-Day Range
$8.85
$24.65
52-Week Range
$2.02
$25.72
Volume
1.97 million shs
Average Volume
3.34 million shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.25

Viking Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.0% Upside
$30.25 Price Target
Short Interest
Bearish
12.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
-0.01mentions of Viking Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$14.60 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.87) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

407th out of 1,018 stocks

Pharmaceutical Preparations Industry

184th out of 498 stocks


VKTX stock logo

About Viking Therapeutics (NASDAQ:VKTX) Stock

Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes. Viking's mission is to bring life-changing treatments to patients with unmet medical needs.

Viking's lead product candidate, VK2809, is a small molecule thyroid beta receptor agonist currently being evaluated in a Phase 2b clinical trial for treating NASH. The company's other product candidates include VK0214, a liver-directed thyroid receptor beta agonist for treating X-linked adrenoleukodystrophy (X-ALD), and VK0612, a novel PPAR-delta agonist for the treatment of type 2 diabetes.

Viking's management team is led by Chief Executive Officer Brian Lian, who joined the company in 2016. Lian has over 25 years of experience in the biotech and pharmaceutical industries, including senior leadership roles at InterMune, Abgenix, and Bristol-Myers Squibb. 

Viking is working hard to grow its revenue. However, the company has yet to turn a profit, reporting a net loss of $68 million in 2022 which increased from 2021's reported $-55 million loss. Viking has also been actively raising capital, recently completing a public offering of common stock.

Viking's current market capitalization is around $1.9 billion, with a price-to-book ratio that aligns with industry peers. Still, some investors see the potential for significant upside if Viking's clinical trials are successful.

Viking's stock price has been volatile over the recent past. The stock has seen a slight uptick recently due to positive news about its drugs in clinical trials. The company's trading volume has been increasing steadily, indicating investor interest.

Viking operates in the highly competitive biotech industry, where companies must navigate complex regulatory environments and rapidly evolving technologies. The NASH market, in particular, is highly competitive, with several large pharmaceutical companies developing therapies for the disease. However, Viking's focus on novel mechanisms of action and expertise in metabolic and endocrine disorders give the company a competitive advantage. Additionally, Viking's partnerships with established biotech companies, such as Ligand Pharmaceuticals and Bayer, provide the company with valuable resources and expertise.

Viking has several potential growth opportunities in the pipeline, including the ongoing Phase 2b clinical trial of VK2809 for treating NASH. If the trial succeeds, Viking could partner with a larger pharmaceutical company to bring the therapy to market. The company's other product candidates, including VK0214 and VK0612, also have the potential to address significant unmet medical needs. Viking has also explored expansion opportunities into new therapeutic areas, such as oncology.

Viking Therapeutics faces a risk from the possibility of regulatory changes affecting the approval of its products. The pharmaceutical industry is heavily regulated, and any changes in regulations or policies could impact Viking's ability to bring its products to market or receive approval for clinical trials. In addition, the company's competitors may also receive approval for similar products, reducing the market share available to Viking.

Risk management is an integral part of any business strategy, and Viking Therapeutics is taking steps to mitigate the risks it faces. The company has a diverse pipeline of products, which helps reduce the impact of any one product failing. Viking is also conducting extensive clinical trials to ensure the safety and efficacy of its products, which could increase the likelihood of approval and reduce the risk of adverse events.

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

Viking Therapeutics (NASDAQ:VKTX) Shares Down 7.7%
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Viking Therapeutics (NASDAQ: VKTX)
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
What 17 Analyst Ratings Have To Say About Viking Therapeutics
Check Out What Whales Are Doing With VKTX
Top Healthcare Stocks for May 2023
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Company Calendar

Last Earnings
4/26/2023
Today
5/27/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.25
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+42.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-68,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.35 per share

Miscellaneous

Free Float
94,105,000
Market Cap
$2.12 billion
Optionable
Optionable
Beta
0.78

Key Executives

  • Brian Lian
    President, Chief Executive Officer & Director
  • Marianne Mancini
    Chief Operating Officer
  • Gregory S. Zante
    Chief Financial Officer
  • Michael Morneau
    Vice President-Finance & Administration













VKTX Stock - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price forecast for 2023?

8 brokers have issued 1-year price targets for Viking Therapeutics' stock. Their VKTX share price forecasts range from $19.00 to $37.00. On average, they expect the company's stock price to reach $30.25 in the next year. This suggests a possible upside of 42.0% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2023?

Viking Therapeutics' stock was trading at $9.40 at the start of the year. Since then, VKTX stock has increased by 126.7% and is now trading at $21.31.
View the best growth stocks for 2023 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings data on Wednesday, April, 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.97%), State Street Corp (5.30%), BlackRock Inc. (2.05%), Boxer Capital LLC (2.01%), Wasatch Advisors LP (1.71%) and RTW Investments LP (1.00%). Insiders that own company stock include Brian Lian, Charles A Rowland Jr, Greg Zante, Lawson Macartney, Ligand Pharmaceuticals Inc, Marianna Mancini and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $21.31.

How much money does Viking Therapeutics make?

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $2.12 billion. The biotechnology company earns $-68,870,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.

This page (NASDAQ:VKTX) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -